In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vifor Fresenius Medical Care Renal Pharma Ltd.

Division of Vifor Pharma Group

Latest From Vifor Fresenius Medical Care Renal Pharma Ltd.

Cara’s Korsuva Impresses Against Pruritus In Hemodialysis Patients

Cara Therapeutics and licensee Vifor Pharma have released positive topline data from the KALM-2 study in chronic kidney disease patients with moderate-to-severe pruritus undergoing hemodialysis, using a first-in-class selective kappa opioid receptor agonist which does not enter the CNS.

Dermatology Clinical Trials

ChemoCentryx Soars On Phase III Avacopan Data In ANCA Vasculitis

The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.

Clinical Trials Immune Disorders

Cara’s Phase III Success In CKD-Pruritus Puts NDA Filing In Sight

Second Phase III study expected later this year, but Cara wants to discuss the possibility of accelerated filing with the US FDA. It also has an oral formulation in Phase II for less severe CKD patients.

Clinical Trials Drug Approval Standards

ChemoCentryx/Vifor Change Tack On EU Avacopan Filing

ChemoCentryx and Vifor Fresenius have changed their conditional marketing authorization application for avacopan to a full MAA in the EU after it emerged that data from the ADVOCATE study will be more comprehensive than expected.

Approvals Europe
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Vifor Pharma Group
  • Senior Management
  • Stefan Schulze, CEO
  • Contact Info
  • Vifor Fresenius Medical Care Renal Pharma Ltd.
    Phone: 58 851 80 00
    Flughofstrasse 61
    Glattbrugg, CH-8152
    Switzerland
UsernamePublicRestriction

Register